Refine your search
753 results found
Dacheng Shanghai | China | 22 Aug 2023
生物医药产业激励措施的新政策解读
为进一步促进中国生物医药产业的发展，除了在国家层面持续发布针对生物医药产业发展的政策之外，中国各个地方也不断制定地区性的针对生物医药产业的激励政策…
Bristows | United Kingdom, USA | 16 Jun 2023
The present and future of SESG for biopharmaceutical companies
Taking effect from 5 January 2023, the European Council has signed the Corporate Sustainability Reporting Directive (the CSRD) into law, meaning that…
Shearman & Sterling LLP | USA | 18 Apr 2023
Massachusetts District Court Grants Motion To Dismiss Securities Fraud Claims Against Biopharmaceutical Company, Finding Plaintiffs Failed To Plead Falsity And Scienter
On March 29, 2023, Judge William G. Young of the United States District Court for the District of Massachusetts granted a motion to dismiss a…
Bristows | European Union, United Kingdom | 5 Apr 2023
Updates to EU and UK competition authority guidance - why the biopharma sector should sit up and take note
Competition authority guidance can make a critical difference for companies seeking to navigate the competition rules in their commercial agreements…
Bristows | European Union, United Kingdom | 11 Jan 2023
A UK Technology Transfer Block Exemption Regulation? What the biopharmaceutical industry may have to say in relation to the CMA’s forthcoming consultation
Amid the planned UK bonfire of EU legislation, the EU Technology Transfer Block Exemption Regulation (TTBER) - which provides a framework for…
Zhong Lun Law Firm | China | 13 Oct 2022
共迎新时代，共创新价值——湾区大健康产业高质量发展论坛回顾
2022年9月26日，广州国际生物岛集团有限公司和中伦律师事务所共同举办的湾区大健康产业高质量发展论坛，以线上直播和线下会议两种形式如期顺利展开。…
Zhong Lun Law Firm | China | 6 Sep 2022
从上市角度详谈生物医药企业与高校、科研院所的合作
校企合作是企业提高研发实力与核心技术的重要方式。而在生物医药行业，企业与高校、科研院所及其科研人员间的合作尤为普遍。据不完全统计…
Zhong Lun Law Firm | China | 2 Aug 2022
生物医药企业投资中的人类遗传资源合规分析
近年来，随着生物医药行业强劲发展以及国家政策鼓励，已有一百多家生物医药企业申报科创板上市。在生物医药企业上市过程中，除惯常问题外…
Lexology PRO | European Union, Italy, Netherlands, etc. | 19 Jul 2021
Dutch enforcer issues first excessive pricing fine
The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
Lexology PRO | United Kingdom | 15 Jul 2021
UK hits pharma companies with £266 million fines for overcharging health service
The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.
